Inventor

BHAT SREENIVAS S

US12 patents

⚠️ This page may combine multiple inventors who share the name “BHAT SREENIVAS S”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

CELGENE CORP

9 patents

USD858741SSep 3, 2019

Pharmaceutical tablet

CELGENE CORP9 citations82

USD835258SDec 4, 2018

Pharmaceutical tablet

CELGENE CORP11 citations82

USD835257SDec 4, 2018

Pharmaceutical tablet

CELGENE CORP10 citations82

USD813372SMar 20, 2018

Pharmaceutical tablet

CELGENE CORP10 citations82

USD787042SMay 16, 2017

Pharmaceutical tablet

CELGENE CORP14 citations82

USD787043SMay 16, 2017

Pharmaceutical tablet

CELGENE CORP13 citations82

US11389454B2Jul 19, 2022

Tablet compositions

CELGENE CORP2 citations68

US12220417B2Feb 11, 2025

Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same

CELGENE CORP0 citations56

US11504378B2Nov 22, 2022

Pharmaceutical compositions comprising (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same

CELGENE CORP0 citations56

SIGNAL PHARM LLC

1 patent

US9198866B2Dec 1, 2015

Pharmaceutical formulations of a substituted diaminopurine

SIGNAL PHARM LLC15 citations89

BHAT SREENIVAS S

1 patent

US8603527B2Dec 10, 2013

Pharmaceutical formulations of a substituted diaminopurine

BHAT SREENIVAS S18 citations85

AMGEN INC

1 patent

US12576034B2Mar 17, 2026

Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione

AMGEN INC0 citations62